Canadian radiopharmaceutical manufacturer DraxImage has received U.S. Nuclear Regulatory Commission approval for its BrachySeed prostate cancer therapy implant. The approval paves the way for Draxis marketing partner Cytogen of Princeton, NJ, to begin U.S. sales, which are expected to commence later this year, according to DraxImage's parent company, DraxisHealth of Mississauga, Ontario.
By AuntMinnie.com staff writersSeptember 22, 2000
Related Reading
Draxis signs brachytherapy seed agreement with Cytogen, September 14, 2000
Collapse in proposed merger of Cytogen, Advanced Magnetics, August 28, 2000
Cytogen revenues slip in Q2, August 8, 2000
Draxis to emphasize radiopharmaceuticals, July 19, 2000
Copyright © 2000 AuntMinnie.com
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
